このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Emergent BioSolutions 将来の成長

Future 基準チェック /46

Emergent BioSolutions利益と収益がそれぞれ年間106.4%と0.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に31.7% 106.6%なると予測されています。

主要情報

106.4%

収益成長率

106.6%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	0.3%
将来の株主資本利益率	31.7%
アナリストカバレッジ	Low
最終更新日	26 Sep 2024

今後の成長に関する最新情報

Recent updates

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Sep 16

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 18

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Aug 02

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

Emergent doses first participant in Phase 1 trial for Lassa virus vaccine

Sep 06

Emergent BioSolutions: Now Long Through Sale Of October Put Spreads

Aug 24

業績と収益の成長予測

NYSE:EBS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,081	13	N/A	N/A	1
12/31/2025	1,196	49	166	183	1
12/31/2024	1,123	-319	146	60	2
6/30/2024	1,102	-587	31	77	N/A
3/31/2024	1,185	-565	-138	-85	N/A
12/31/2023	1,049	-760	-264	-206	N/A
9/30/2023	1,103	-778	-216	-146	N/A
6/30/2023	1,072	-602	-602	-280	N/A
3/31/2023	974	-394	-523	-181	N/A
12/31/2022	1,118	-212	-394	-34	N/A
9/30/2022	1,491	33	-180	201	N/A
6/30/2022	1,581	88	127	292	N/A
3/31/2022	1,757	158	78	279	N/A
12/31/2021	1,774	220	96	320	N/A
9/30/2021	1,653	227	23	237	N/A
6/30/2021	1,709	299	121	326	N/A
3/31/2021	1,706	387	300	483	N/A
12/31/2020	1,577	306	385	537	N/A
9/30/2020	1,333	167	262	413	N/A
6/30/2020	1,259	170	184	305	N/A
3/31/2020	1,108	68	41	141	N/A
12/31/2019	1,106	55	91	188	N/A
9/30/2019	1,016	4	-181	-100	N/A
6/30/2019	878	-18	-15	77	N/A
3/31/2019	855	42	66	148	N/A
12/31/2018	782	63	-30	42	N/A
9/30/2018	706	100	221	285	N/A
6/30/2018	681	113	96	146	N/A
3/31/2018	562	67	N/A	165	N/A
12/31/2017	561	83	N/A	208	N/A
9/30/2017	519	81	N/A	118	N/A
6/30/2017	512	68	N/A	110	N/A
3/31/2017	503	61	N/A	54	N/A
12/31/2016	489	63	N/A	55	N/A
9/30/2016	497	73	N/A	70	N/A
6/30/2016	512	94	N/A	148	N/A
3/31/2016	529	125	N/A	153	N/A
12/31/2015	489	91	N/A	43	N/A
9/30/2015	478	79	N/A	93	N/A
6/30/2015	457	59	N/A	67	N/A
3/31/2015	460	35	N/A	76	N/A
12/31/2014	404	54	N/A	112	N/A
9/30/2014	400	22	N/A	69	N/A
6/30/2014	351	14	N/A	50	N/A
3/31/2014	324	19	N/A	72	N/A
12/31/2013	313	31	N/A	97	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EBSは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。

収益対市場: EBS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EBS今後 3 年以内に収益を上げることが予想されます。

収益対市場: EBSの収益 ( 1.6% ) US市場 ( 8.8% ) よりも低い成長が予測されています。

高い収益成長: EBSの収益 ( 1.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EBSの自己資本利益率は、3年後には高くなると予測されています ( 31.7 %)

Emergent BioSolutions 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 14%

Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024

Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. Updates Earnings Guidance for the Year 2023

Price target decreased by 55% to US$5.00

Recent updates

Consensus estimates of losses per share improve by 14%

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Emergent BioSolutions’ ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

High number of new directors

Emergent BioSolutions Inc. to Report Q2, 2024 Results on Aug 06, 2024

Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Index

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Emergent BioSolutions Inc. to Report Q1, 2024 Results on May 01, 2024

New minor risk - Market cap size

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Full year 2023 earnings: EPS misses analyst expectations

Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. to Report Q4, 2023 Results on Mar 06, 2024

New CEO Appointment A Clear Positive For Emergent BioSolutions

New major risk - Share price stability

Emergent BioSolutions Inc. Announces Changes in CEO

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Emergent BioSolutions Inc. announced delayed 10-Q filing

Emergent BioSolutions Inc. Updates Earnings Guidance for the Year 2023

Price target decreased by 55% to US$5.00

Emergent BioSolutions Inc. to Report Q3, 2023 Results on Nov 02, 2023

Emergent Biosolutions Inc. Announces Board Appointments

Emergent Biosolutions' Narcan®? Nasal Spray Launches over the Counter Making It Possible for Everyone to Help Save A Life from an Opioid Overdose Emergency

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Emergent BioSolutions Inc. Announces Executive Changes

Emergent BioSolutions Inc. to Report Q2, 2023 Results on Aug 08, 2023

Emergent BioSolutions Inc. Receives U.S. FDA Approval of CYFENDUS ( Anthrax Vaccine Adsorbed, Adjuvanted), A Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions: Making A Big Bet On Narcan

Emergent BioSolutions Inc. Announces Resignation of Robert G. Kramer Sr. as President and Member of the Company's Board

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Value-Defensive Index

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Consensus EPS estimates fall by 35%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Emergent Biosolutions Inc. Revises Earnings Guidance for the Full Year of 2023

Consensus EPS estimates upgraded to US$1.85 loss

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Consensus EPS estimates fall by 79%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Emergent Biosolutions Q4 2022 Earnings Preview

Emergent BioSolutions Inc. Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Investor sentiment improves as stock rises 15%

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Emergent BioSolutions Inc. to Report Q4, 2022 Results on Feb 27, 2023

Emergent Biosolutions Inc. Announces Executive Changes

Emergent BioSolutions Inc. Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-The-Counter NARCAN® (Naloxone HCI) Nasal Spray

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Consensus EPS estimates fall by 283%

Price target decreased to US$36.80

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2022

Emergent BioSolutions Inc. Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

Consensus forecasts updated